PDS Biotechnology (STU:EU6) Change In Payables And Accrued Expense : €-1.99 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology Change In Payables And Accrued Expense?

PDS Biotechnology's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €1.03 Mil. It means PDS Biotechnology's Accounts Payable & Accrued Expense increased by €1.03 Mil from Dec. 2024 to Mar. 2025 .

PDS Biotechnology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-4.66 Mil. It means PDS Biotechnology's Accounts Payable & Accrued Expense declined by €4.66 Mil from Dec. 2023 to Dec. 2024 .

PDS Biotechnology Change In Payables And Accrued Expense Historical Data

The historical data trend for PDS Biotechnology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Change In Payables And Accrued Expense Chart

PDS Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.70

0.31

5.70

-0.12

-4.66

PDS Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-1.56	-2.34	0.52	-1.20	1.03

PDS Biotechnology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.99 Mil.

PDS Biotechnology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

PDSB:USA

Address

303A College Road, East Princeton, NJ, USA, 08540

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology Headlines

No Headlines